Abstract 352P
Background
Breast cancer (BC) and its treatment could disturb the reproductive system. We identified reproductive system disorders following chemotherapy in patients with BC and the determinant factors.
Methods
One hundred and twelve married female patients with BC who underwent first chemotherapy between 2018 and 2020 in Dr. Sardjito Hospital, Yogyakarta were recruited. Socio-demographic and clinical data were collected at baseline. After each chemotherapy session, the patients were interviewed about symptoms of reproductive system disorder (irregular menstruation, vaginal dryness, decreased libido, dyspareunia, delayed orgasm and anorgasmia) and other symptoms (fatigue, anorexia, nausea and anxiety). We used a questionnaire based on the CTCAE version 4. Data of symptoms were collected until patients received at least 3 treatment cycles. Chi square and Fisher’s exact tests were used to analyze any association among variables.
Results
The most common symptoms were vaginal dryness (41.1%) followed by decreased libido (39.3%). In the subgroup analysis, the most common symptom among 44 pre-menopause women was irregular menstruation (84.1%). Vaginal dryness occurred more in cases with anthracycline-based regimen (p=0.036) and with anxiety (p=0.019), compared to their counterparts. Decreased libido presented more in cases with younger age (p=0.037) and positive ER status (p=0.009). Irregular menstruation, dyspareunia, delayed orgasm, and anorgasmia did not correlate with any of the determinant factors.
Conclusions
Reproductive system disorders occurred very frequently in the local BC patients after receiving chemotherapy. Influencing factors included anthracycline-based regimen, anxiety, age, and estrogen receptor status.
Clinical trial identification
Editorial acknowledgement
Erik Christopher Hookom, BA, M.Ed, TEFL Office of Research and Publication, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Legal entity responsible for the study
The authors.
Funding
The Indonesian Ministry of Research, Technology, and Higher Education; Public Funding, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session